Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.

@article{Huggins2011BackgroundAR,
  title={Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.},
  author={Alison B Huggins and Robert C. Sergott},
  journal={Current opinion in ophthalmology},
  year={2011},
  volume={22 6},
  pages={447-50}
}
Introduction The modern treatment era for remitting-relapsing multiple sclerosis (RRMS) began in 1993 with the introduction of betaseron into the clinical practice. Before that disease-modifying medication was available, only symptomatic treatment with a variety of corticosteroid preparations was available. No treatment options were available to prevent multiple relapses that often lead to significant disability. 

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

References

Publications referenced by this paper.
Showing 1-6 of 6 references

Long-term fingolimod [FTY720] in relapsing MS: 5-year results from an extension of phase II multicenter study show a sustained low level of disease activity

G Izquierdo, P O’Connor, X Montalban
Presented in poster form at the American Academy of Neurology Meeting; • 2011

Mechanism of action of oral fingolimod [FTY70] in multiple sclerosis

J Chun, Hartung H-P
Clin Neuropharmacol • 2010

et al., for the TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

JA Cohen, F Barkof, G Comi
N Engl J Med • 2010

Similar Papers

Loading similar papers…